Johnson & Johnson Net Change in Short-term Investments 2010-2025 | JNJ

Johnson & Johnson annual/quarterly net change in short-term investments history and growth rate from 2010 to 2025. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
  • Johnson & Johnson net change in short-term investments for the quarter ending June 30, 2025 was $0M, a 0% increase year-over-year.
  • Johnson & Johnson net change in short-term investments for the twelve months ending June 30, 2025 was $0M, a 0% increase year-over-year.
  • Johnson & Johnson annual net change in short-term investments for 2024 was $0B, a 0% decline from 2023.
  • Johnson & Johnson annual net change in short-term investments for 2023 was $0B, a 0% decline from 2022.
  • Johnson & Johnson annual net change in short-term investments for 2022 was $0B, a 0% decline from 2021.
Johnson & Johnson Annual Net Change in Short-term Investments
(Millions of US $)
2024 $N/A
2023 $N/A
2022 $N/A
2021 $N/A
2020 $N/A
2019 $N/A
2018 $N/A
2017 $N/A
2016 $N/A
2015 $N/A
2014 $N/A
2013 $N/A
2012 $N/A
2011 $N/A
2010 $N/A
2009 $N/A
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $431.791B $88.821B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $673.574B 44.07
AbbVie (ABBV) United States $372.037B 19.89
Novartis AG (NVS) Switzerland $268.235B 14.53
Roche Holding AG (RHHBY) Switzerland $260.064B 0.00
Novo Nordisk (NVO) Denmark $254.416B 15.40
Merck (MRK) United States $218.231B 11.44
Pfizer (PFE) United States $147.142B 7.63
Sanofi (SNY) France $126.091B 12.49
Bayer (BAYRY) Germany $32.695B 6.16
Innoviva (INVA) United States $1.270B 12.52